Molecular mechanisms underlying bacterial resistance to ceftazidime/avibactam.

Adult Humans Ceftazidime / pharmacology Microbial Sensitivity Tests Anti-Bacterial Agents / pharmacology beta-Lactamases / genetics
ceftazidime/avibactam efflux pump outer membrane protein resistance mechanism β-lactamase

Journal

WIREs mechanisms of disease
ISSN: 2692-9368
Titre abrégé: WIREs Mech Dis
Pays: United States
ID NLM: 9918227353306676

Informations de publication

Date de publication:
11 2022
Historique:
revised: 01 05 2022
received: 07 03 2022
accepted: 07 05 2022
pubmed: 28 7 2022
medline: 15 11 2022
entrez: 27 7 2022
Statut: ppublish

Résumé

Ceftazidime/avibactam (CAZ/AVI), a combination of ceftazidime and a novel β-lactamase inhibitor (avibactam) that has been approved by the U.S. Food and Drug Administration, the European Union, and the National Regulatory Administration in China. CAZ/AVI is used mainly to treat complicated urinary tract infections and complicated intra-abdominal infections in adults, as well as to treat patients infected with Carbapenem-resistant Enterobacteriaceae (CRE) susceptible to CAZ/AVI. However, increased clinical application of CAZ/AVI has resulted in the development of resistant strains. Mechanisms of resistance in most of these strains have been attributed to bla

Identifiants

DOI: 10.1002/wsbm.1571 PMID: 35891616 PMC: PMC9788277
pubmed: 35891616
doi: 10.1002/wsbm.1571
pmc: PMC9788277
doi:

Substances chimiques

Ceftazidime 9M416Z9QNR
avibactam 7352665165
Anti-Bacterial Agents 0
beta-Lactamases EC 3.5.2.6

Types de publication

Journal Article Review Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e1571

Informations de copyright

© 2022 The Authors. WIREs Mechanisms of Disease published by Wiley Periodicals LLC.

Références

Antimicrob Agents Chemother. 2012 Jul;56(7):3753-7
pubmed: 22526311
J Mol Biol. 2019 Aug 23;431(18):3472-3500
pubmed: 30959050
J Antimicrob Chemother. 2018 Jun 1;73(6):1525-1529
pubmed: 29566151
Antimicrob Agents Chemother. 2015 Oct;59(10):6605-7
pubmed: 26195508
Clin Microbiol Infect. 2019 Jun;25(6):763.e5-763.e8
pubmed: 30928562
Antimicrob Agents Chemother. 2018 Jun 26;62(7):
pubmed: 29760124
Nat Rev Microbiol. 2019 May;17(5):295-306
pubmed: 30837684
Clin Infect Dis. 2016 Oct 1;63(7):954-958
pubmed: 27313265
Euro Surveill. 2020 Jan;25(3):
pubmed: 31992391
mSphere. 2019 Mar 27;4(2):
pubmed: 30918055
Antimicrob Agents Chemother. 2018 Aug 27;62(9):
pubmed: 29941650
Antimicrob Agents Chemother. 2014;58(4):1835-46
pubmed: 24379206
Antimicrob Agents Chemother. 2019 Sep 16;:
pubmed: 31527032
Drugs. 2018 Apr;78(6):675-692
pubmed: 29671219
Open Forum Infect Dis. 2017 Jul 01;4(3):ofx101
pubmed: 28685153
WIREs Mech Dis. 2022 Nov;14(6):e1571
pubmed: 35891616
J Antimicrob Chemother. 2017 May 1;72(5):1373-1385
pubmed: 28158732
J Antimicrob Chemother. 2018 Oct 1;73(10):2782-2788
pubmed: 30010894
Antimicrob Agents Chemother. 2020 Sep 21;64(10):
pubmed: 32660988
mBio. 2017 Oct 31;8(5):
pubmed: 29089425
Antimicrob Agents Chemother. 2019 Mar 27;63(4):
pubmed: 30617091
Antimicrob Agents Chemother. 2017 Jun 27;61(7):
pubmed: 28461318
Antimicrob Agents Chemother. 2022 Feb 15;66(2):e0200021
pubmed: 34807753
J Antimicrob Chemother. 2015 Oct;70(10):2779-86
pubmed: 26089439
Antimicrob Agents Chemother. 2018 Nov 26;62(12):
pubmed: 30249690
Int J Antimicrob Agents. 2020 Jul;56(1):106011
pubmed: 32417206
Antimicrob Agents Chemother. 2015 Sep;59(9):5324-30
pubmed: 26100712
Antimicrob Agents Chemother. 2017 Oct 24;61(11):
pubmed: 28848018
J Mol Biol. 2001 Oct 12;313(1):1-12
pubmed: 11601842
Antimicrob Agents Chemother. 2020 Jul 22;64(8):
pubmed: 32457107
Antimicrob Agents Chemother. 2020 Dec 16;65(1):
pubmed: 33139291
Infect Control Hosp Epidemiol. 2010 May;31(5):476-84
pubmed: 20334553
J Antimicrob Chemother. 2010 Nov;65(11):2376-81
pubmed: 20801783
Clin Microbiol Infect. 2011 Aug;17(8):1135-41
pubmed: 21635663
J Antimicrob Chemother. 2015;70(6):1650-8
pubmed: 25645206
Clin Microbiol Infect. 2020 Apr;26(4):516.e1-516.e4
pubmed: 31740422
Clin Infect Dis. 2020 Dec 23;71(Suppl 4):S436-S439
pubmed: 33367577
J Antimicrob Chemother. 2019 Sep 1;74(9):2588-2595
pubmed: 31225882
J Antimicrob Chemother. 2013 Oct;68(10):2286-90
pubmed: 23696619
Ann Clin Microbiol Antimicrob. 2020 Apr 1;19(1):14
pubmed: 32238155
JAMA. 2015 Oct 13;314(14):1479-87
pubmed: 26436831
Antimicrob Agents Chemother. 2014 Oct;58(10):5704-13
pubmed: 25022578
J Antimicrob Chemother. 2019 May 1;74(5):1241-1243
pubmed: 30753572
Antimicrob Agents Chemother. 2017 Apr 24;61(5):
pubmed: 28242667
Antimicrob Agents Chemother. 2018 Apr 26;62(5):
pubmed: 29507064
Antimicrob Agents Chemother. 2020 May 21;64(6):
pubmed: 32253219
mSphere. 2020 Aug 26;5(4):
pubmed: 32848008
Antimicrob Agents Chemother. 2018 Feb 23;62(3):
pubmed: 29263067
Antimicrob Agents Chemother. 2020 Mar 24;64(4):
pubmed: 31964792
Antimicrob Agents Chemother. 2017 May 24;61(6):
pubmed: 28396547
J Antimicrob Chemother. 2020 Feb 1;75(2):384-391
pubmed: 31742604
Expert Rev Anti Infect Ther. 2011 Aug;9(8):653-79
pubmed: 21819331
J Med Chem. 2015 May 14;58(9):3682-92
pubmed: 25782055
J Glob Antimicrob Resist. 2021 Dec;27:132-141
pubmed: 34478880
Proc Natl Acad Sci U S A. 2012 Jul 17;109(29):11663-8
pubmed: 22753474
J Infect Chemother. 2015 Feb;21(2):148-51
pubmed: 25444674
Clin Infect Dis. 2017 Feb 1;64(3):257-264
pubmed: 28013264
Clin Microbiol Infect. 2020 Jul;26(7):946.e1-946.e3
pubmed: 32061796
Antimicrob Agents Chemother. 2017 Nov 22;61(12):
pubmed: 28947473
Antimicrob Resist Infect Control. 2020 Oct 27;9(1):166
pubmed: 33109242
Clin Microbiol Infect. 2020 Jan;26(1):124.e1-124.e4
pubmed: 31494252
Braz J Infect Dis. 2021 Nov-Dec;25(6):101647
pubmed: 34774471
Antimicrob Agents Chemother. 2017 Sep 22;61(10):
pubmed: 28739787
J Antimicrob Chemother. 2017 Sep 1;72(9):2483-2488
pubmed: 28637339
J Clin Microbiol. 2020 Aug 24;58(9):
pubmed: 32580951
J Antimicrob Chemother. 2018 Oct 1;73(10):2777-2781
pubmed: 30010951
Antimicrob Agents Chemother. 2017 Feb 23;61(3):
pubmed: 28031201
Clin Microbiol Infect. 2021 Jul;27(7):1040.e1-1040.e6
pubmed: 33775814
Antimicrob Agents Chemother. 2015 Feb;59(2):1020-9
pubmed: 25451057
Antimicrob Agents Chemother. 2017 Aug 24;61(9):
pubmed: 28674059
Int J Antimicrob Agents. 2020 Sep;56(3):106045
pubmed: 32522673
Antimicrob Agents Chemother. 2016 Aug 22;60(9):5454-8
pubmed: 27381386
Emerg Microbes Infect. 2021 Dec;10(1):2042-2051
pubmed: 34551677
Drugs. 2010 Apr 16;70(6):651-79
pubmed: 20394454
Antimicrob Agents Chemother. 2015 Jul;59(7):3700-9
pubmed: 25691639
Int J Antimicrob Agents. 2018 Nov;52(5):697-701
pubmed: 30081137
Antimicrob Agents Chemother. 2019 Mar 27;63(4):
pubmed: 30670424
Antimicrob Agents Chemother. 2017 Apr 24;61(5):
pubmed: 28223379
J Antimicrob Chemother. 2015 Aug;70(8):2279-86
pubmed: 25957381
Antimicrob Agents Chemother. 2015 Sep;59(9):5793-7
pubmed: 26169413
J Antimicrob Chemother. 2017 Dec 01;72(12):3342-3348
pubmed: 28962008
MMWR Morb Mortal Wkly Rep. 2010 Jun 25;59(24):750
pubmed: 20577157
J Antimicrob Chemother. 2018 Dec 1;73(12):3336-3345
pubmed: 30247546
Clin Microbiol Infect. 2022 Jan;28(1):136.e1-136.e6
pubmed: 34044150
Antimicrob Agents Chemother. 2015 Dec 14;60(3):1349-59
pubmed: 26666933
J Antimicrob Chemother. 2004 Aug;54(2):410-7
pubmed: 15254025
Antimicrob Agents Chemother. 2015 Aug;59(8):5029-31
pubmed: 26014931
Antimicrob Agents Chemother. 2017 Feb 23;61(3):
pubmed: 28031200
FEMS Microbiol Rev. 2012 Mar;36(2):340-63
pubmed: 21707670
Int J Antimicrob Agents. 2020 Sep;56(3):106111
pubmed: 32721602
Antimicrob Agents Chemother. 2021 Nov 17;65(12):e0116021
pubmed: 34606331
Antimicrob Agents Chemother. 2017 Jul 25;61(8):
pubmed: 28559260

Auteurs

Luying Xiong (L)

Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, the First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China.

Xueting Wang (X)

Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, the First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China.

Yuan Wang (Y)

Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, the First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China.

Wei Yu (W)

Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, the First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China.

Yanzi Zhou (Y)

Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, the First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China.

Xiaohui Chi (X)

Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, the First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China.

Tingting Xiao (T)

Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, the First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China.

Yonghong Xiao (Y)

Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, the First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China.
Jinan Microecological Biomedicine Shandong Laboratory, Jinan, China.
ORCID: 0000-0003-4845-5904

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Personnes › Tranches d'âge › Adulte › Molecular mechanisms underlying bacterial...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Molecular mechanisms underlying bacterial...
questionsmedicales.fr › Composés hétérocycliques › Composés hétérocycliques à cycles fusionnés › Composés hétérobicycliques › bêta-Lactames › Céphalosporines › Céfaloridine › Ceftazidime › Molecular mechanisms underlying bacterial...
questionsmedicales.fr › Techniques d'investigation › Évaluation préclinique de médicament › Tests de sensibilité microbienne › Molecular mechanisms underlying bacterial...
questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Utilisations thérapeutiques › Anti-infectieux › Antibactériens › Molecular mechanisms underlying bacterial...
questionsmedicales.fr › Enzymes et coenzymes › Enzymes › Hydrolases › Amidohydrolases › bêta-Lactamases › Molecular mechanisms underlying bacterial...